EUVIMEDEUVIMED entdecken
Crossref

Clopidogrel–indobufen conjugates as dual antiplatelet prodrugs with enhanced bioactivation and synchronized pharmacokinetic–pharmacodynamic profiles in rats

Zhe Zhang, Dongchen Qin, Jiaxin Song, Huan Yang, Jingkai Gu, Yingjie Guo, Dong Sun

Drug Metabolism and Disposition · 2026-01 · 54 (1) · 100212

DOI: 10.1016/j.dmd.2025.100212 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-01. Verfasst von Zhe Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Drug Metabolism, School of Life Science, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Clopidogrel, Prodrugs, Platelet Aggregation Inhibitors. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Jilin University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A dual prodrug linking clopidogrel and indobufen-an established dual antiplatelet therapy combination-was designed to enhance the bioactivation of clopidogrel while enabling coordinated inhibition of the ADP and thromboxane A2 pathways of platelet activation. Because these 2 agents differ markedly in mechanism and duration of action, conventional combination therapy necessitates asymmetrical dosing. The fixed 1:1 molar ratio imposed by covalent conjugation introduces an inherent constraint on achieving balanced dual-pathway inhibition, a key consideration for defining the conjugate's therapeutic positioning. Three conjugates-deuterated clopidogrel-indobufen (1a), clopidogrel-indobufen (1b), and clopidogrel-(S)-indobufen (1c)-were synthesized and evaluated in rats. A single dose of these conjugates produced a delayed time to maximum plasma concentration and a sustained-release profile for both active metabolites. Covalent conjugation enhanced systemic exposure to the clopidogrel active metabolite while reducing exposure to released indobufen. Because conjugates 1b and 1c exhibited pharmacokinetic profiles more comparable to equimolar coadministration, they were selected for pharmacodynamic assessment. ADP receptor P2Y12 occupancy and plasma thromboxane B2 served as pathway-specific biomarkers, each bridging the pharmacokinetics and pharmacodynamics of the irreversible inhibition by clopidogrel and the reversible inhibition by indobufen, respectively. Both biomarkers showed strong correlations with inhibition of the corresponding platelet activation pathways. A single dose of 1b or 1c yielded synchronized maximal inhibition of both pathways at 8 hours-4 hours later than conventional coadministration-while retaining comparable peak efficacy. In the repeated dosing study, assessments aligned with the maximal-effect time point of the coadministration reference demonstrated that both conjugates-when supplemented with an interdose of indobufen-achieved pathway inhibition equivalent to the clinical regimen. These findings support conjugates 1b and 1c as promising alternatives to standard clopidogrel therapy and as potential tools for controlled de-escalation of antiplatelet therapy. SIGNIFICANCE STATEMENT: The clopidogrel-indobufen dual prodrugs enable synchronous, sustained release of both antiplatelet species in rats. P2Y12 receptor occupancy and plasma thromboxane B2 effectively capture the pharmacokinetic-pharmacodynamic relationships of this irreversible/reversible dual-antagonist combination.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelProdrugsPlatelet Aggregation InhibitorsAnimalsRatsMaleRats, Sprague-Dawley

Stichwörter der Autor:innen

ClopidogrelDual antiplatelet therapyDual prodrugIndobufenP2Y(12) receptor occupancy

Substanzen

ClopidogrelProdrugsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Research Center for Drug Metabolism, School of Life Science, Jilin University, Changchun, China.
  • Research Center for Drug Metabolism, School of Life Science, Jilin University, Changchun, China; State Key Laboratory of Supramolecular Structure and Materials, Center for Supramolecular Chemical Biology, College of Che…
  • School of Life Science, Jilin University, Changchun, China. Electronic address: guoyingjie@jlu.edu.cn.
  • Research Center for Drug Metabolism, School of Life Science, Jilin University, Changchun, China. Electronic address: sun_dong@jlu.edu.cn.

Förderung

  • Jilin University
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Z., Qin, D., Song, J., Yang, H., Gu, J., Guo, Y., & Sun, D. (2026). Clopidogrel–indobufen conjugates as dual antiplatelet prodrugs with enhanced bioactivation and synchronized pharmacokinetic–pharmacodynamic profiles in rats. Drug Metabolism and Disposition, 54(1), 100212. https://doi.org/10.1016/j.dmd.2025.100212

Vancouver

Zhang Z, Qin D, Song J, Yang H, Gu J, Guo Y, et al. Clopidogrel–indobufen conjugates as dual antiplatelet prodrugs with enhanced bioactivation and synchronized pharmacokinetic–pharmacodynamic profiles in rats. Drug Metabolism and Disposition. 2026;54(1):100212. doi:10.1016/j.dmd.2025.100212

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhe and Qin, Dongchen and Song, Jiaxin and Yang, Huan and Gu, Jingkai and Guo, Yingjie and Sun, Dong},
  title = {Clopidogrel–indobufen conjugates as dual antiplatelet prodrugs with enhanced bioactivation and synchronized pharmacokinetic–pharmacodynamic profiles in rats},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {1},
  pages = {100212},
  doi = {10.1016/j.dmd.2025.100212}
}
Kostenlos starten →